Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M706884200 on September 18, 2007

J. Biol. Chem., Vol. 282, Issue 46, 33389-33395, November 16, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/46/33389    most recent
M706884200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geraghty, P.
Right arrow Articles by McElvaney, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geraghty, P.
Right arrow Articles by McElvaney, N. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Secretory Leucocyte Protease Inhibitor Inhibits Interferon-{gamma}-induced Cathepsin S Expression*

Patrick Geraghty, Catherine M. Greene, Michael O'Mahony, Shane J. O'Neill, Clifford C. Taggart1, and Noel G. McElvaney

From the Pulmonary Research Division, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin 9, Ireland

Received for publication, August 17, 2007 , and in revised form, September 12, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
We have demonstrated that bronchoalveolar lavage fluid from chronic obstructive pulmonary disease patients contains higher levels of interferon-{gamma} compared with controls. Interferon-{gamma} is a potent inducer of various cathepsins and matrix metalloproteases. Therefore, we postulated that interferon-{gamma} could induce protease expression by macrophages in acute and chronic lung disease. Chronic obstructive pulmonary disease patients had greater levels of cathepsin S and matrix metalloprotease-12 in their bronchoalveolar lavage fluid. Macrophages incubated with chronic obstructive pulmonary disease bronchoalveolar lavage fluid exhibited increased expression of cathepsin S and matrix metalloprotease-12, which was inhibited by the addition of interferon-{gamma}-neutralizing immunoglobulin. Human secretory leukocyte protease inhibitor is an 11.7-kDa cationic non-glycosylated antiprotease synthesized and secreted by cells at the site of inflammation. We have demonstrated that secretory leukocyte protease inhibitor can inhibit interferon-{gamma}-induced cathepsin S production by macrophages. Pretreatment of macrophages with secretory leukocyte protease inhibitor inhibited interferon-{gamma}-induced inhibitor {kappa}B beta degradation and activation of nuclear factor {kappa}B. Secretory leukocyte protease inhibitor may prove to be therapeutically important as a potential inhibitor of protease expression in chronic obstructive pulmonary disease.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Chronic obstructive pulmonary disease (COPD)2 is a major public health problem currently ranked as the fourth leading cause of death in the world (1). It is characterized by airflow limitation and is principally associated with exposure to cigarette smoke. However, the link between cigarette smoke, bronchial inflammation, and the development of airflow limitation is not completely understood, as 15–20% of smokers develop COPD. One hypothesis is that individuals who develop exhibit an exaggerated inflammatory response to cigarette smoke COPD caused by an immune system that is already primed by previous infections or by the possession of inherited genetic polymorphisms.

A number of investigators have shown an increased numbers of T cells in the lungs of patients with COPD (2–4) and that disease progression is linked to lymphocyte (T cell) infiltration. CD4+ and CD8+ T cells are increased in the airways and lung parenchyma of COPD patients (4). In addition, CD4+ and CD8+ T cells are activated with increased expression of IFN-{gamma} in COPD patients (5).

IFN-{gamma} is produced by many cell types, including T-cells and B-cells, and is an important component of the antiviral response. It stimulates both macrophages and NK cells and is involved in the regulation of the immune and inflammatory responses. IFN-{gamma} is also released predominantly by Th1 cells, and recruits leukocytes to a site of infection, resulting in increased inflammation. It activates macrophages for the expression of surface major histocompatibility class II antigens, costimulatory molecules, and inflammatory mediators for tumoricidal and antimicrobial activity. It regulates the proliferation and death of T lymphocytes, promotes the development of a type 1 T-helper cell response, and is essential for the control of many intracellular pathogens in vivo. IFN-{gamma} mRNA or protein has been shown in mouse and human lung macrophages (6), spleen (7), bone marrow (8, 9), resting peritoneum (10), and peritoneal exudate following sterile inflammation (11).

The primary families of proteases released into the extracellular space following cell activation include members of the serine protease, matrix metalloprotease (MMP), and cysteinyl cathepsin groups of proteases. Proteases play important roles in numerous biological processes and are capable of degrading many extracellular matrix components and as such are regarded as pivotal in the pathogenesis of COPD. MMPs are produced by a wide variety of cell types including epithelium, fibroblasts, neutrophils, and macrophages. Several MMPs (including MMP-12) have been implicated in the pathogenesis of chronic lung injury, particularly in emphysema. This is shown in MMP-12 knock-out mice, who do not develop air space enlargement in response to smoke exposure (12).

Macrophages also synthesize cysteinyl cathepsins, which are ubiquitous lysosomal proteases (13–15). Cytokines and microbial products have previously been demonstrated to regulate cathepsin expression and activity (16, 17). IFN-{gamma} has been shown to be a potent inducer of cathepsin S in monocytes and keratinocytes (18). IL-1 and TNF-{alpha} also induce cathepsin S activity, while exposure to IL-10 prevents conversion of procathepsin S into its mature form (16). IL-13 has been shown to induce cathepsins B, H, K, L, and S (19). We have shown previously that cathepsins cleave and inactivate key innate immunity proteins including human beta-defensins 2 and 3 (20), secretory leukocyte protease inhibitor (SLPI) (21), and lactoferrin (22).

SLPI is an 11.7-kDa nonglycosylated protein produced at mucosal surfaces, primarily the upper respiratory tract (23) and is an important antiprotease (24). SLPI suppresses LPS-induced activation of NF-{kappa}B, production of nitric oxide, and TNF-{alpha} (25). Interestingly, IFN-{gamma} can suppress expression of SLPI (26). In a model of acute lung injury, prior administration of SLPI attenuated pulmonary recruitment of neutrophils and decreased lung injury (27). We have recently shown that SLPI is taken up into monocytes and becomes distributed within the cytoplasm and nucleus and can bind NF-{kappa}B DNA binding regions within the IL-8 and TNF-{alpha} promoters (28). SLPI can also diminish p65 binding, thereby attenuating inflammation in monocytes (28).

We postulated that COPD is associated with a Th1 cytokine profile with IFN-{gamma} plays a central role in activity of macrophages leading to proteolysis of lung tissue. We further propose that SLPI could dampen this protease burden not by its direct antiprotease effect but by its antiinflammatory effects. To test this theory we investigated cytokine and protease levels in bronchoalveolar lavage fluid (BAL) fluid from control and COPD patients. Macrophage protease expression was also investigated following activation with IFN-{gamma} stimuli and potential inhibition of protease expression induced by IFN-{gamma} was evaluated in the presence of SLPI. The data from this study provide further evidence of an impaired protease/antiprotease balance in COPD patients because of a Th1 response that can be inhibited by SLPI.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Culture and Stimulation of Monocyte Cells—Myelomonocytic cells (U937) (European Collection of Cell Cultures Health Protection Agency, Salisbury, Wiltshire, UK) (5 x 105 cells/ml) were cultured in RPMI 1640 medium (Invitrogen) and were differentiated to macrophage-like cells with PMA for 48 h. The macrophage-like cells were incubated in fresh medium for a further 2 days before stimulation. Stimulation was performed with IFN-{gamma} (R & D Systems, 10 units/ng) for 3 or 24 h before harvesting, for RNA or protein isolation, respectively. SLPI, {alpha}1-antitrypsin (A1AT), and Elafin (each at 10 µg/ml) stimulation was administered an hour prior to IFN-{gamma}. Cells were also stimulated with BAL fluid from COPD patients for 2 h, washed three times, and resuspended in serum free medium for a further 48 h. Mouse anti-IFN-{gamma} (R&D Systems) (500 ng/ml) or mouse IgG2A (R&D Systems) (500 ng/ml) was incubated for 30 min at 37 °C with COPD BAL fluid prior to cell stimulation. Cells were also treated for 1 h with SN50 and its inactive control, SN50M (Calbiochem) prior to IFN-{gamma} stimuli to block NF-{kappa}B activity.

Isolation of PBMCs—Mononuclear cells were isolated from heparinized venous peripheral blood obtained from healthy volunteers using LymphoprepTM (Nycomed, Norway). Briefly, freshly collected EDTA-peripheral blood samples (7.5 ml) were diluted 1:1 in 0.9% NaCl and 2 ml of 10% dextran (Sigma) was added and incubated at room temperature for 15 min. Afterward the upper layer containing the mixed leukocyte fraction was removed and overlayered onto 5 ml of LymphoprepTM. The sample was then centrifuged at 200 x g for 10 min. The mononuclear cell interphase band was aspirated and washed three times in HBSS medium. Monocytes were purified to 97% cell purity using the EasySep human CD14 selection mixture as recommended by the manufacturers (StemCell Technologies, London England). Monocytes were then cultured in RPMI containing 40% autologous serum, penicillin G (final concentration 100 units/ml), and streptomycin sulfate (final concentration 100 µg/ml) at 37 °C in a 5% CO2 atmosphere for 9 days (29). An hour prior to stimulation, cells were washed and incubated in serum-free medium.

BAL Fluid Samples—Samples of BAL fluid and serum were obtained from subjects with COPD (n = 17) and healthy volunteers (n = 15). Ethical approval was obtained from Beaumont Hospital Ethics Committee and informed consent from each of the patients undergoing bronchoscopy. Subjects underwent flexible fiberoptic bronchoscopy and bronchoalveolar lavage (BAL) was performed. Samples were separated into cell suspension and supernatant.

IFN-{gamma} Levels Measured by Sandwich ELISA—The concentration of IFN-{gamma} was measured by ELISA using cytokine-specific Abs (R&D Systems, Abingdon, UK). Values are expressed as picograms per ml.

Semiquantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)—After treatment with IFN-{gamma}, cells were harvested in Tri reagent (Sigma-Ireland), and RNA was extracted as detailed in the manufacturer's protocol. Total RNA (2 µg) was reverse-transcribed at 37 °C with 1 mM deoxynucleotide mix (Promega, Southampton, UK), 1.6 µg of oligo-p[dT]15 primer (Roche, Lewes, UK), and 1 µl M-MLV reverse transcriptase (Promega, Southampton, UK) in a 20-µl volume as described in the manufacturer's protocol. 2 µl of each cDNA was amplified with 1.25 units of TaqDNA polymerase, 1x PCR buffer, and 10 mM dNTPs (Promega) in a 50 µl volume containing 100 pmol each of the following primers: 5'-ATG AAA CGG CTG GTT TGT GT-3' and 5'-CTA GAT TTC TGG GTA AGA GGG AAA GCT AGC-3' for cathepsin S; 5'-CTG GAC AAC TCA ACT CTG GCA A-3' and 5'-ATT ATA GAT CCT GTA AGT GAG GTA CCG C-3' for MMP-12; 5'-GAA GGT GAA GGT CGG AGT CA-3' and 5'-TTC ACA CCC ATG ACG AAC AT-3' for GAPDH; 5'-GCC GGG AAA TCG TGC GTG-3' and 5'-GGG TAC ATG GTG GTG CCG-3' for beta-actin PCR products were quantified densitometrically at cycle numbers between 10 and 40 to determine the appropriate cycle number at which exponential amplification of products was occurring, and to identify the cycle number at which sufficient discrimination was possible to accurately quantify increases or decreases in gene expression. After a hot start, the amplification profile was 30 cycles of 1 min denaturation at 94 °C, 1 min annealing at 58 °C, and 1 min extension at 72 °C for cathepsin S, MMP-12. GAPDH, and beta-actin gene amplification required only 20 cycles. RT-PCR amplification of cathepsin S, MMP-12, beta-actin and GAPDH generated products of 1000, 703, 307, and 402 bp, respectively. PCR products were commercially sequenced (MWG Biotech AG, Ebersberg, Germany) to verify gene identity. PCR products were resolved on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide (Sigma). The ratio of PCR fragment intensities of each gene relative to GAPDH and beta-actin was determined by densitometry.

Presence of Cathepsin S—Cathepsin S activity was determined in supernatants from macrophage-like cells 24 h after stimulation with or without IFN-{gamma} or BAL fluid. Cathepsin S activity was determined in 100 µl of each BAL sample using the substrate Z-Phe-Arg-pNA (0.1 mM). The reaction buffer used for cathepsin S activity estimation was 0.2 M sodium acetate, pH 7.5, 2 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 1 µM pepstatin, and 2 mM Pefabloc. The samples were incubated with substrate for 60 min at 37 °C, and fluorescence (substrate turnover) was determined by excitation at 355 nm and emission at 460 nm. Results were expressed as a change (delta) in fluorescence units over a 60-min period (FU).

Western Blot—BAL fluid from healthy controls and COPD patients were investigated for the presence of MMP-12. Supernatant from U937 macrophages treated with IFN-{gamma} were investigated for cathepsin S and MMP-12. BAL fluid or concentrated media from macrophage-like cells were separated by electrophoresis on 12% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (Sigma-Aldrich), which was probed using mouse anti-MMP-12 antibody (R&D Systems), rabbit anti-cathepsin B antibody (Calbiochem), or mouse anti-cathepsin S antibody (Calbiochem). A rabbit anti-MMP-12 (Calbiochem, Oncogene Research Products) antibody was used to detect MMP-12 from cells treated with COPD BAL fluid plus mouse anti-IFN-{gamma} antibody or mouse IgG2A, to minimize antibody interaction. Binding was detected using the appropriate horseradish peroxidase-conjugated secondary antibodies and visualized by chemiluminescence (Pierce).

Preparation of Subcellular Fractions—U937 cells were activated with NE and nuclear and cytoplasmic extracts were isolated. Briefly cells were washed and resuspended in 1 ml of ice-cold phosphate-buffered saline and kept on ice for 5 min. Cells were lifted from plates with a cell scraper and pelleted by centrifugation at 10,000 rpm for 5 min at 4 °C. The supernatant was removed, and the cell pellet was resuspended in 1 ml of hypotonic buffer (10 mM Hepes (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol) (Sigma). Cells were pelleted by centrifugation at 14,000 rpm for 10 min at 4 °C and then lysed for 10 min on ice in 20 µl of hypotonic buffer containing 0.1% Igepal CA-630. Lysates were centrifuged as before, and the cytoplasmic extract was removed. The remaining nuclear pellet was lysed in 15 µl of lysis buffer (20 mM Hepes (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM phenylmethylsulfonyl fluoride) (Sigma) for 15 min on ice. After centrifugation at 14,000 rpm for 10 min at 4 °C, nuclear extracts were removed into 35 µl of storage buffer (10 mM Hepes (pH 7.9), 50 mM KCl, 0.2 mM EDTA, 20% (v/v) glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol). Protein concentrations of cytoplasmic and nuclear extracts were determined, and extracts were stored at–80 °C until required for use.


Figure 1
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 1.
IFN-{gamma} levels in control and COPD patients and IFN-{gamma} effect on protease production in U937s. A, IFN-{gamma} levels in COPD and controls. B, RT-PCR was carried out on mRNA from differentiated U937 cells treated with IFN-{gamma} to amplify regions of the cathepsin S, MMP-12, GAPDH, and beta-actin genes. The quantification of the expression of cathepsin S and MMP-12 was assessed compared with beta-actin and GAPDH from U937 macrophages. C, panel i, cathepsin S activity was determined using the Z-Phe-Arg-AMC substrate (pH 7.5). Panel ii, Western blot analysis for cathepsin S (36 kDa) and MMP-12 (45 kDa) levels in supernatants recovered from U937 macrophages exposed to IFN-{gamma}. Protein loading was corrected for sample protein concentrations. Experiments were performed at least three times and representative data and S.E. are shown. A statistical significance is highlighted with its appropriate p value.

 
NF-{kappa}B Activity ELISA—The effect of IFN-{gamma} and SLPI on NF-{kappa}B activity was determined using the TransAM NF-{kappa}B ELISA (Active Motif), using nuclear protein fractions.

Densitometric Analysis—Gels were analyzed by densitometry and compared in a semiquantitative manner using the GeneGenius Gel Documentation and analysis system (Cambridge, UK) and GeneSnap and GeneTools software. All expression values were verified by at least three independent experiments.

Statistical Analysis—Data were analyzed with the PRISM 3.0 software package (GraphPad, San Diego, CA). Results are expressed as the mean ± S.D. and were compared by Student's t test. Differences were considered significant at p ≤ 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
IFN-{gamma} in COPD and Effect on Protease Expression in Macrophages—IFN-{gamma} levels in BAL fluid were determined by ELISA and were found to be significantly elevated in COPD individuals versus controls (72.85 ± 28.61 versus 11.16 ± 6.19 pg/ml, p = 0.0484) (Fig. 1A).

IFN-{gamma}-induced protease mRNA expression was examined in U937 macrophages. Macrophages were exposed to 25 ng/ml IFN-{gamma} for 3 h. Cathepsin S and MMP-12 mRNA expression levels were investigated by RT-PCR (Fig. 1B). IFN-{gamma} significantly increased expression of cathepsin S and MMP-12 in U937 macrophages (p = 0.0147 and 0.0049, respectively). The effect of IFN-{gamma} stimulation on release of cathepsin S and MMP-12 from U937 macrophages was investigated. Elevated cathepsin S activity was observed when cells were stimulated with IFN-{gamma}, using the cathepsin substrate Z-Phe-Arg-AMC, at pH 7.5 (Fig. 1C, panel i). A statistically significant difference for cathepsin S activity between the control and cells stimulated with 10 ng/ml IFN-{gamma} was observed (p = 0.0013). This was further confirmed by Western blot, which demonstrated the increased production of cathepsin S by IFN-{gamma} stimulated U937 macrophages (Fig. 1C, panel ii).

Western blot demonstrated that there was increased MMP-12 release from IFN-{gamma} stimulated U937 macrophages (Fig. 1C, panel ii). Increased MMP-9 activity was observed in U937 macrophages but was most likely due to the presence of small quantities of PMA in the cell medium (data not included). A change in MMP-9 activity was not observed when using similar experiments with PBM macrophages (data not included).

IFN-{gamma}-induced Protease Expression—Neutrophil elastase (NE), cathepsin, and MMP levels were measured in COPD and control BAL fluid. NE activity was not detected in COPD or control samples, however elevated cathepsin S activity was observed in COPD compared with control BAL fluid (Fig. 2A, p = 0.0268). Western blot demonstrated the presence of MMP-12 in COPD, but not control BAL fluid (Fig. 2B).

Levels of cathepsin S and MMP-12 from U937 macrophages exposed to COPD BAL fluid were also evaluated. Elevated cathepsin S activity was observed when cells were stimulated with COPD BAL fluid compared with untreated cells (Fig. 2C) (p = 0.0011). An anti IFN-{gamma} neutralizing antibody significantly inhibited this effect (p = 0.0073) (Fig. 2C). A mouse IgG2A antibody (isotype control) was also added to COPD BAL fluid and then to cells and was shown to have no inhibitory effects on the COPD BAL fluid induced cathepsin S production (p = 0.8495). The increase in cathepsin S by COPD BAL fluid was further demonstrated by Western blot (Fig. 2D, panel i). COPD BAL fluid exposure also increased MMP-12 protein levels, demonstrated by Western blot (Fig. 2D, panel ii). The anti-IFN-{gamma} antibody had the same inhibition effect on MMP-12 expression in macrophages exposed to COPD BAL fluid.

Effect of SLPI on IFN-{gamma}-induced Protease Expression—IFN-{gamma}-induced protease mRNA expression was further examined by the pretreatment of macrophages with SLPI prior to IFN-{gamma} stimulation. U937 and PBM macrophages were exposed to 10 µg/ml SLPI followed by 10 ng/ml IFN-{gamma}. Cathepsin S and 12 mRNA expression levels were investigated by RT-PCR from U937 macrophages (Fig. 3A). IFN-{gamma} significantly increased expression of cathepsin S and MMP-12 even at 10 ng/ml IFN-{gamma}. SLPI significantly decreased the gene expression of cathepsin S (p = 0.0061). A reduced level of cathepsin S activity was observed when U937 (Fig. 3B) and PBM (Fig. 3D) macrophages were incubated firstly with SPLI follow by IFN-{gamma}, using the cathepsin substrate Z-Phe-Arg-AMC, at pH 7.5. A statistically significant decrease in cathepsin S activity was observed between cells stimulated with 10 ng/ml IFN-{gamma}, and cells incubated with SLPI and IFN-{gamma} (p = 0.0229 and 0.023 for U937s and PBM, respectively). Exposing U937 macrophages to A1AT or elafin prior to IFN-{gamma} stimulation had no significant effect on IFN-{gamma}-induced cathepsin S activity (Fig. 3B). No reduction in MMP-12 was observed when U937 (Fig. 3C) and PBM macrophages (Fig. 3D) were incubated firstly with SPLI follow by IFN-{gamma}.


Figure 2
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 2.
Protease profile from control and COPD BAL fluid and macrophages exposed to COPD BAL fluid. A, cathepsin S activity from control and COPD BAL fluid was determined using the Z-Phe-Arg-pNA substrate (pH 7.5). B, MMP-12 Western blot of control and COPD BAL fluid. The 22-kDa bands represent the catalytic domain of human MMP-12. C, cathepsin S activity was determined after 24 h following a 2-h stimulation with COPD BAL fluid or COPD BAL fluid plus anti-IFN-{gamma} or isotype control. A statistical significance is highlighted with its appropriate p value. D, Western blot analysis for cathepsin S (panel i) and MMP-12 (panel ii) levels in supernatants recovered from U937 macrophages exposed to COPD BAL fluid or COPD BAL fluid plus anti-IFN-{gamma}/isotype control antibody. Protein loading was corrected for sample protein concentrations. Experiments were performed at least three times, and representative data and S.E. are shown.

 
Effect of SLPI on IFN-{gamma}-signaling Pathways in Macrophages—SLPI inhibited IFN-{gamma}-induced I{kappa}-Bbeta degradation (Fig. 4A). Similarly NF-{kappa}B activation was observed after 3 h in the presence of IFN-{gamma} (Fig. 4B) and IFN-{gamma}-induced NF-{kappa}B nuclear translocation was increased 2-fold compared with control. IFN-{gamma}-induced NF-{kappa}B activation was also inhibited by SLPI.

SN50, a cell-permeable peptide that inhibits NF-{kappa}B nuclear translocation downstream of IKK, and its mutant peptide, NF-{kappa}B SN50M, were used to investigate whether inhibition of NF-{kappa}B could reduce IFN-{gamma}-induced protease expression. SN50 was able to inhibit IFN-{gamma}-induced cathepsin S (Fig. 4C, p = 0.022) demonstrating that IFN-{gamma} signals via NF-{kappa}B to induce cathepsin S expression in macrophages.


Figure 3
View larger version (31K):
[in this window]
[in a new window]

  		FIGURE 3.
Inhibitory effects of SLPI on IFN-{gamma}-induced protease gene expression and protein release. A, RT-PCR was carried out on mRNA from differentiated U937 cells treated with SLPI, IFN-{gamma}, and SLPI followed by IFN-{gamma} to amplify regions of the cathepsin S, -12, beta-actin, and GAPDH genes. The quantification of the expression of cathepsin S and -12 was assessed compared with beta-actin and GAPDH from U937 macrophages. B, cathepsin S activity was determined after 24 h following incubation of U937s with IFN-{gamma}, antiprotease (SLPI, elafin, or A1AT) or preincubation with an antiprotease followed by IFN-{gamma}. C, MMP-12 levels were examined after incubation of U937s with IFN-{gamma}, SLPI or SLPI followed by IFN-{gamma}. D, cathepsin S activity was determined 24 h after incubating PBM-derived macrophages with IFN-{gamma}, SLPI, or SLPI followed by IFN-{gamma}. E, MMP-12 levels were examined after incubating PBM-derived macrophages with IFN-{gamma}, SLPI, or SLPI followed by IFN-{gamma}. Protein loading was corrected for sample protein concentrations. Experiments were performed at least three times, and representative data and S.E. are shown.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Proteases have been implicated in COPD as a cause of airway inflammation and parenchymal destruction (2, 30). Although a prominent role for NE has been postulated in COPD for many years, recent work has demonstrated that cathepsins and matrix metalloproteases, produced primarily by macrophages, are also important (31). In addition to macrophages and neutrophils as modulators of inflammation in COPD, an increasing number of authors have described an important role for lymphocytes (2–4, 32). We postulated that increased IFN-{gamma} observed in COPD would induce expression of these proteases (cathepsins and MMPs). This study demonstrates significantly elevated levels of IFN-{gamma}, cathepsin S, and MMP-12 in COPD BAL fluid compared with control BAL fluid We have further demonstrated that incubation of macrophages with IFN-{gamma} leads to increased cathepsin S and MMP-12 expression and that the neutralization of IFN-{gamma} activity in COPD BAL fluid decreases COPD BAL fluid-induced cathepsin S and MMP-12 expression by macrophages. Finally, we have demonstrated that SLPI can down-regulate IFN-{gamma}-induced protease production, via inactivation of the NF-{kappa}B signaling pathway. Therefore, these studies provide molecular and clinical data to support the view that IFN-{gamma} up-regulation leads to expression of proteases responsible for lung tissue damage in COPD and that this is remediable by the anti-inflammatory effects of SLPI.

Both CD4+ and CD8+ T cells are increased in the COPD lung, with CD8+ cells being predominant (33) evidence that COPD is predominantly a Th1 driven condition. In general, Th1 responses preferentially stimulate genes that are involved in apoptosis and tissue injury (34). The Th1 cells observed in COPD are the major potential source of IFN-{gamma} in the lungs.

It has been shown that some of the mediators involved in the inflammatory process observed in emphysematous tissues can directly induce emphysema. IFN-{gamma} is one of those candidates. Transgenic overexpression of IFN-{gamma} in the adult murine lung results in pulmonary emphysema (35). BAL fluids from the overexpressing IFN-{gamma} mice have increased neutrophil and lymphocyte levels and an exaggerated number of macrophages compared with controls (35). Elevated levels of IFN-{gamma} alter the pulmonary protease/antiprotease balance in a proteolytic direction via the induction of MMPs and a variety of cathepsins (35). Production of high amounts of IFN-{gamma} (~20 ng/ml) has been reported with dendritic cell populations after stimulation with IL-12/IL-18 (7, 36, 37).


Figure 4
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 4.
SLPI inhibits IFN-{gamma}-induced NF-{kappa}B activation. A, I{kappa}-Bbeta degradation was analyzed by Western blot using an anti-I{kappa}-Bbeta antibody and cytosolic extracts (10 µg) from control (–), IFN-{gamma}-treated, SLPI-treated, or IFN-{gamma}/SLPI-treated macrophages (10 ng/ml IFN-{gamma}, 180 min). B, NF-{kappa}B activation was measured using the TransAM NF-{kappa}B activity ELISA in nuclear extracts (2 µg) from control (–) and IFN-{gamma}-treated macrophages (10 ng/ml, 180 min) ± SLPI (10 µg/ml). C, cathepsin S activity was determined using the Z-Phe-Arg-AMC substrate 24 h after stimulation with IFN-{gamma}. Cells were treated for 60 min with SN50 (1µg/ml) and its inactive control (SN50M) (Calbiochem), prior to treated macrophages with IFN-{gamma} (10 ng/ml), to block NF-{kappa}B activity. Protein loading was corrected for sample protein concentrations. Experiments or analyses of results were performed at least three times, and representative data and S.E. are shown.

 
In this study cathepsin S and MMP-12 gene expressions and protein activity were increased in macrophages exposed to IFN-{gamma}. This increase in proteases can have a major impact on innate host defenses in the lung, as we have previously shown that cathepsin S can cleave and inactivate human beta-defensin 2 and 3 (21), SLPI (21) and lactoferrin (23). The cleavage of SLPI by cathepsin S results in the loss of the active site of SLPI and the inactivation of SLPI antineutrophil elastase capacity, further worsening the potential protease burden. IFN-{gamma} also down-regulates SLPI (26, 38) via CCR-5, and we have previously shown decreased levels of SLPI in the COPD lung mediated in part by cathepsin degradation (21). Cathepsin S has been identified as the dominant endocytic protease that is specifically up-regulated under inflammatory conditions in the presence of IFN-{gamma} (39). Cathepsin S up-regulation in COPD is extremely relevant in the context of recent data showing that cathepsin S inhibition (and a null mutation of cathepsin S) decreases IFN-{gamma}-induced DNA injury, apoptosis, emphysema, inflammation, and protease accumulation in a murine pulmonary emphysema modeling system (40).

MMP-12 has also been implicated the pathogenesis of chronic lung injury, particularly emphysema. MMP–12 is elevated in the lungs of COPD patients (31). Interestingly, MMP-12 knock-out mice do not develop air space enlargement in response to smoke exposure, implicating MMP-12 in development of cigarette smoke induced emphysema (12). The increased expression of this important MMP in our study driven by IFN-{gamma} is therefore of interest.

SLPI possesses anti-inflammatory activity (41). LPS hyporesponsive cells transcribe SLPI and transfection of macrophages with SLPI suppresses LPS-induced activation of NF-{kappa}B, production of nitric oxide and TNF-{alpha} by an unknown mechanism (25). IFN-{gamma} can suppress expression of SLPI and restore LPS responsiveness to SLPI-producing cells (25). We have previously shown that SLPI can inhibit LPS and lipoteichoic acid (LTA)-induced NF-{kappa}B activation in monocytic cells by preventing degradation of key regulatory proteins, like I{kappa}B{alpha} and I{kappa}Bbeta (42, 43). SLPI prevents the degradation of I{kappa}B{alpha} and beta without affecting I{kappa}B{alpha} phosphorylation and ubiquitination (42). SLPI inhibition of IFN-{gamma}-induced I{kappa}B beta-degradation and NF-{kappa}B activation is due to the anti-inflammatory activity of SLPI (28). SLPI ability to inhibit IFN-{gamma}-induced NF-kB activation also resulted in decreased cathepsin S expression but not MMP-12 production. The inability of SLPI to inhibit IFN-{gamma}-induced MMP-12 may be due in part to activation of MMP-12 expression via another transcription factor pathway other than NF-{kappa}B. Recently, Churg et al. (44) have demonstrated that another anti-protease, A1AT, can inhibit cigarette smoke induced MMP-12 and TNF-{alpha} via inactivation of PAR-1 by inhibiting thrombin and plasmin. This further demonstrates the important anti-inflammatory functions of classically described antiproteases. Further investigation of the interaction of SLPI with the IFN-{gamma} pathway would be beneficial.

In conclusion, we have demonstrated that a Th1 response leads to increased production of a spectrum of proteases driven by IFN-{gamma}. Inhibition of IFN-{gamma} in COPD BAL fluid inhibits this process. Therefore, by minimizing the IFN-induced protease expression, SLPI is of potential therapeutic relevance in the treatment of COPD.


   FOOTNOTES
 
* This work was supported in part by the Health Research Board, The Alpha One Foundation, Science Foundation Ireland, Cystic Fibrosis Research Trust, and Cystic Fibrosis Association of Ireland. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Pulmonary Research Division, RCSI Education, and Research Center, Smurfit Bldg., Beaumont Hospital, Dublin 9, Ireland. Tel.: 00353-18093712; Fax: 00353-1-8093808; E-mail: ctaggart{at}rcsi.ie.

2 The abbreviations used are: COPD, chronic obstructive pulmonary disease; SLPI, secretory leucocyte protease inhibitor; BALF, bronchoalveolar lavage fluid; IFN-{gamma}, interferon-{gamma}; MMP, matrix metalloprotease; A1AT, {alpha}1-antitrypsin; I{kappa}B beta, inhibitor {kappa}B beta; NF-{kappa}B, nuclear factor {kappa}B; Z, benzyloxycarbonyl; NE, neutrophil elastase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL, interleukin; TNF, tumor necrosis factor. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Pauwels, R. A., Buist, A. S., Ma, P., Jenkins, C. R., and Hurd, S. S. (2001) Respir. Care 46, 798–825[Medline] [Order article via Infotrieve]
  2. Saetta, M., Di Stefano, A., Turato, G., Facchini, F. M., Corbino, L., Mapp, C. E., Maestrelli, P., Ciaccia, A., and Fabbri, L. M. (1998) Am. J. Respir. Crit. Care Med. 157, 822–826[Abstract/Free Full Text]
  3. Lams, B. E., Sousa, A. R., Rees, P. J., and Lee, T. H. (2000) Eur. Respir. J. 15, 512–516[Abstract]
  4. O'Shaughnessy, T. C., Ansari, T. W., Barnes, N. C., and Jeffery, P. K. (1997) Am. J. Respir. Crit Care Med. 155, 852–857[Abstract]
  5. Grumelli, S., Corry, D. B., Song, L. Z., Song, L., Green, L., Huh, J., Hacken, J., Espada, R., Bag, R., Lewis, D. E., and Kheradmand, F. (2004) PLoS Med. 1, e8[CrossRef][Medline] [Order article via Infotrieve]
  6. Fenton, M. J., Vermeulen, M. W., Kim, S., Burdick, M., Strieter, R. M., and Kornfeld, H. (1997) Infect Immun. 65, 5149–5156[Abstract]
  7. Ohteki, T., Fukao, T., Suzue, K., Maki, C., Ito, M., Nakamura, M., and Koyasu, S. (1999) J. Exp. Med. 189, 1981–1986[Abstract/Free Full Text]
  8. Fukao, T., Frucht, D. M., Yap, G., Gadina, M., O'Shea, J. J., and Koyasu, S. (2001) J. Immunol. 166, 4446–4455[Abstract/Free Full Text]
  9. Fultz, M. J., Barber, S. A., Dieffenbach, C. W., and Vogel, S. N. (1993) Int. Immunol. 5, 1383–1392[Abstract/Free Full Text]
  10. Puddu, P., Fantuzzi, L., Borghi, P., Varano, B., Rainaldi, G., Guillemard, E., Malorni, W., Nicaise, P., Wolf, S. F., Belardelli, F., and Gessani, S. (1997) J. Immunol. 159, 3490–3497[Abstract]
  11. Schindler, H., Lutz, M. B., Rollinghoff, M., and Bogdan, C. (2001) J. Immunol. 166, 3075–3082[Abstract/Free Full Text]
  12. Hautamaki, R. D., Kobayashi, D. K., Senior, R. M., and Shapiro, S. D. (1997) Science 277, 2002–2004[Abstract/Free Full Text]
  13. Nagler, D. K., Zhang, R., Tam, W., Sulea, T., Purisima, E. O., and Menard, R. (1999) Biochemistry 38, 12648–12654[CrossRef][Medline] [Order article via Infotrieve]
  14. Guncar, G., Podobnik, M., Pungercar, J., Strukelj, B., Turk, V., and Turk, D. (1998) Structure 6, 51–61[Medline] [Order article via Infotrieve]
  15. Turk, D., Podobnik, M., Kuhelj, R., Dolinar, M., and Turk, V. (1996) FEBS Lett. 384, 211–214[CrossRef][Medline] [Order article via Infotrieve]
  16. Fiebiger, E., Meraner, P., Weber, E., Fang, I. F., Stingl, G., Ploegh, H., and Maurer, D. (2001) J. Exp. Med. 193, 881–892[Abstract/Free Full Text]
  17. Moriuchi, H., Moriuchi, M., and Fauci, A. S. (2000) J. Virol. 74, 6849–6855[Abstract/Free Full Text]
  18. Schwarz, G., Boehncke, W. H., Braun, M., Schroter, C. J., Burster, T., Flad, T., Dressel, D., Weber, E., Schmid, H., and Kalbacher, H. (2002) J. Investig. Dermatol. 119, 44–49[CrossRef][Medline] [Order article via Infotrieve]
  19. Zheng, T., Zhu, Z., Wang, Z., Homer, R. J., Ma, B., Riese, R. J., Jr., Chapman, H. A., Jr., Shapiro, S. D., and Elias, J. A. (2000) J. Clin. Investig. 106, 1081–1093[Medline] [Order article via Infotrieve]
  20. Taggart, C. C., Greene, C. M., Smith, S. G., Levine, R. L., McCray, P. B., Jr., O'Neill, S., and McElvaney, N. G. (2003) J. Immunol. 171, 931–937[Abstract/Free Full Text]
  21. Taggart, C. C., Lowe, G. J., Greene, C. M., Mulgrew, A. T., O'Neill, S. J., Levine, R. L., and McElvaney, N. G. (2001) J. Biol. Chem. 276, 33345–33352[Abstract/Free Full Text]
  22. Rogan, M. P., Taggart, C. C., Greene, C. M., Murphy, P. G., O'Neill, S. J., and McElvaney, N. G. (2004) J. Infect Dis. 190, 1245–1253[CrossRef][Medline] [Order article via Infotrieve]
  23. Abe, T., Kobayashi, N., Yoshimura, K., Trapnell, B. C., Kim, H., Hubbard, R. C., Brewer, M. T., Thompson, R. C., and Crystal, R. G. (1991) J. Clin. Investig. 87, 2207–2215[Medline] [Order article via Infotrieve]
  24. Gauthier, F., Fryksmark, U., Ohlsson, K., and Bieth, J. G. (1982) Biochim. Biophys. Acta 700, 178–183[CrossRef][Medline] [Order article via Infotrieve]
  25. Jin, F. Y., Nathan, C., Radzioch, D., and Ding, A. (1997) Cell 88, 417–426[CrossRef][Medline] [Order article via Infotrieve]
  26. Odaka, C., Mizuochi, T., Yang, J., and Ding, A. (2003) J. Immunol. 171, 1507–1514[Abstract/Free Full Text]
  27. Lentsch, A. B., Jordan, J. A., Czermak, B. J., Diehl, K. M., Younkin, E. M., Sarma, V., and Ward, P. A. (1999) Am. J. Pathol. 154, 239–247[Abstract/Free Full Text]
  28. Taggart, C. C., Cryan, S. A., Weldon, S., Gibbons, A., Greene, C. M., Kelly, E., Low, T. B., O'Neill, S. J., and McElvaney, N. G. (2005) J. Exp. Med. 202, 1659–1668[Abstract/Free Full Text]
  29. Punturieri, A., Filippov, S., Allen, E., Caras, I., Murray, R., Reddy, V., and Weiss, S. J. (2000) J. Exp. Med. 192, 789–799[Abstract/Free Full Text]
  30. Finkelstein, R., Fraser, R. S., Ghezzo, H., and Cosio, M. G. (1995) Am. J. Respir. Crit. Care Med. 152, 1666–1672[Abstract]
  31. Molet, S., Belleguic, C., Lena, H., Germain, N., Bertrand, C. P., Shapiro, S. D., Planquois, J. M., Delaval, P., and Lagente, V. (2005) Inflamm. Res. 54, 31–36[CrossRef][Medline] [Order article via Infotrieve]
  32. Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., Cherniack, R. M., Rogers, R. M., Sciurba, F. C., Coxson, H. O., and Pare, P. D. (2004) N. Engl. J. Med. 350, 2645–2653[Abstract/Free Full Text]
  33. Saetta, M., Baraldo, S., Corbino, L., Turato, G., Braccioni, F., Rea, F., Cavallesco, G., Tropeano, G., Mapp, C. E., Maestrelli, P., Ciaccia, A., and Fabbri, L. M. (1999) Am. J. Respir. Crit. Care Med. 160, 711–717[Abstract/Free Full Text]
  34. Sandler, N. G., Mentink-Kane, M. M., Cheever, A. W., and Wynn, T. A. (2003) J. Immunol. 171, 3655–3667[Abstract/Free Full Text]
  35. Wang, Z., Zheng, T., Zhu, Z., Homer, R. J., Riese, R. J., Chapman, H. A., Jr., Shapiro, S. D., and Elias, J. A. (2000) J. Exp. Med. 192, 1587–1600[Abstract/Free Full Text]
  36. Schleicher, U., Hesse, A., and Bogdan, C. (2005) Blood 105, 1319–1328[Abstract/Free Full Text]
  37. Hochrein, H., Shortman, K., Vremec, D., Scott, B., Hertzog, P., and O'Keeffe, M. (2001) J. Immunol. 166, 5448–5455[Abstract/Free Full Text]
  38. Ma, B., Kang, M. J., Lee, C. G., Chapoval, S., Liu, W., Chen, Q., Coyle, A. J., Lora, J. M., Picarella, D., Homer, R. J., and Elias, J. A. (2005) J. Clin. Investig. 115, 3460–3472[CrossRef][Medline] [Order article via Infotrieve]
  39. Wiendl, H., Lautwein, A., Mitsdorffer, M., Krause, S., Erfurth, S., Wienhold, W., Morgalla, M., Weber, E., Overkleeft, H. S., Lochmuller, H., Melms, A., Tolosa, E., and Driessen, C. (2003) J. Neuroimmunol. 138, 132–143[CrossRef][Medline] [Order article via Infotrieve]
  40. Zheng, T., Kang, M. J., Crothers, K., Zhu, Z., Liu, W., Lee, C. G., Rabach, L. A., Chapman, H. A., Homer, R. J., Aldous, D., Desanctis, G., Underwood, S., Graupe, M., Flavell, R. A., Schmidt, J. A., and Elias, J. A. (2005) J. Immunol. 174, 8106–8115[Abstract/Free Full Text]
  41. Hiemstra, P. S., Fernie-King, B. A., McMichael, J., Lachmann, P. J., and Sallenave, J. M. (2004) Curr. Pharm. Des. 10, 2891–2905[CrossRef][Medline] [Order article via Infotrieve]
  42. Taggart, C. C., Greene, C. M., McElvaney, N. G., and O'Neill, S. (2002) J. Biol. Chem. 277, 33648–33653[Abstract/Free Full Text]
  43. Greene, C. M., McElvaney, N. G., O'Neill, S. J., and Taggart, C. C. (2004) Infect Immun 72, 3684–3687[Abstract/Free Full Text]
  44. Churg, A., Wang, X., Wang, R. D., Meixner, S. C., Pryzdial, E. L., and Wright, J. L. (2007) Am. J. Respir. Cell Mol. Biol. 37, 144–151[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/46/33389    most recent
M706884200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geraghty, P.
Right arrow Articles by McElvaney, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geraghty, P.
Right arrow Articles by McElvaney, N. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement